INS and metabolic disease: Of note, LINK‐A LNAs treatment alleviated obesity and metabolic disorders in mice, as evidenced by weight loss, reduced fasting glucose, and increased insulin sensitivity (Figure 7c–e; Figure S4e, Supporting information).